Manfred Klevesath

949 total citations
19 papers, 709 citations indexed

About

Manfred Klevesath is a scholar working on Oncology, Hepatology and Cancer Research. According to data from OpenAlex, Manfred Klevesath has authored 19 papers receiving a total of 709 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Hepatology and 8 papers in Cancer Research. Recurrent topics in Manfred Klevesath's work include Liver physiology and pathology (10 papers), Pancreatic and Hepatic Oncology Research (7 papers) and Cancer, Hypoxia, and Metabolism (5 papers). Manfred Klevesath is often cited by papers focused on Liver physiology and pathology (10 papers), Pancreatic and Hepatic Oncology Research (7 papers) and Cancer, Hypoxia, and Metabolism (5 papers). Manfred Klevesath collaborates with scholars based in Germany, United States and United Kingdom. Manfred Klevesath's co-authors include Arnie Purushotham, Stephen W. Duffy, Lynda G. Bobrow, Keith Millar, Jonathan P. Myles, Sara Upponi, Sarah E. Pinder, Gerald S. Falchook, Andreas Johne and David S. Hong and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Surgery.

In The Last Decade

Manfred Klevesath

19 papers receiving 685 citations

Peers

Countries citing papers authored by Manfred Klevesath

Since Specialization

Citations

This map shows the geographic impact of Manfred Klevesath's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manfred Klevesath with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manfred Klevesath more than expected).

Fields of papers citing papers by Manfred Klevesath

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manfred Klevesath. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manfred Klevesath. The network helps show where Manfred Klevesath may publish in the future.

Co-authorship network of co-authors of Manfred Klevesath

This figure shows the co-authorship network connecting the top 25 collaborators of Manfred Klevesath. A scholar is included among the top collaborators of Manfred Klevesath based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manfred Klevesath. Manfred Klevesath is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	A Code of Digital Ethics: laying the foundation for digital ethics in a science and technology company 2022 ·AI & Society ·(unknown), (unknown), Simon Lucas, (unknown), Manfred Klevesath, (unknown)	11
2	Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose 2021 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), Manja Friese‐Hamim, Andreas Johne, Christopher Stroh, Manfred Klevesath, Gerald S. Falchook, David S. Hong, Pascal Girard, Samer El Bawab	17
3	Forward Thinking for Sustainable Business Value: A New Method for Impact Valuation 2020 ·Sustainability ·Herwig Buchholz, Thomas S. Eberle, Manfred Klevesath, (unknown), (unknown), (unknown), (unknown)	13
4	First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors 2019 ·Clinical Cancer Research ·Gerald S. Falchook, Razelle Kurzrock, Hesham M. Amin, (unknown), Siqing Fu, Sarina A. Piha‐Paul, Filip Jankú, Ghazaleh Eskandari, Daniel V.T. Catenacci, Manfred Klevesath, Rolf Bruns, Uz Stammberger, Andreas Johne, Friedhelm Bladt, Manja Friese‐Hamim, Pascal Girard, Samer El Bawab, David S. Hong	67
5	Abstract 4510: Model-based phase II dose selection of c-Met inhibitor MSC2156119J 2015 ·Cancer Research ·(unknown), Samer El Bawab, Friedhelm Bladt, Michael Meyring, Manfred Klevesath, Gerald S. Falchook, David S. Hong, Andreas Johne, Pascal Girard	2
6	Results of the first-in-human phase I trial assessing MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in patients (pts) with advanced solid tumors. 2014 ·Journal of Clinical Oncology ·Gerald S. Falchook, David S. Hong, Hesham M. Amin, Siqing Fu, Sarina A. Piha‐Paul, Filip Jankú, (unknown), Hongxia Zheng, Manfred Klevesath, (unknown), Friedhelm Bladt, Andreas Johne, Razelle Kurzrock	10
7	Abstract CT236: MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in patients with advanced solid tumors: results of the first-in-human phase I trial 2014 ·Cancer Research ·Gerald S. Falchook, David S. Hong, Hesham M. Amin, Siqing Fu, Sarina A. Piha‐Paul, Filip Jankú, (unknown), (unknown), Manfred Klevesath, (unknown), Friedhelm Bladt, Andreas Johne, Razelle Kurzrock	1
8	Patterns of metastatic spread in early breast cancer 2013 ·The Breast ·Manfred Klevesath, Klaus Pantel, Andrew O. Agbaje, Elena Provenzano, Gordon Wishart, Peter J. Gough, Sarah E. Pinder, Stephen W. Duffy, Arnie Purushotham	27
9	A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma 2013 ·Investigational New Drugs ·Antoine Hollebecque, Éric Deutsch, C. Massard, Carlos Gomez‐Roca, Ratislav Bahleda, Vincent Ribrag, C. Bourgier, Vladimir Lazar, Ludovic Lacroix, (unknown), Andréa Varga, T. de Baère, Frank Beier, (unknown), (unknown), Frank T. Zenke, Manfred Klevesath, Jean‐Charles Soria	23
10	Phase I study of oral selective c-Met inhibitor EMD 1214063 in pts with advanced solid tumors. 2013 ·Journal of Clinical Oncology ·Gerald S. Falchook, David S. Hong, Hesham M. Amin, Siqing Fu, Sarina A. Piha‐Paul, Filip Jankú, Vivek Subbiah, Aung Naing, Jennifer J. Wheler, Manfred Klevesath, (unknown), Andreas Johne, Friedhelm Bladt, Razelle Kurzrock	3
11	First-in-human phase I dose-escalation study of the oral selective C-met inhibitor EMD 1204831 in patients with advanced solid tumors. 2012 ·Journal of Clinical Oncology ·Hesham M. Amin, Gerald S. Falchook, Siqing Fu, David S. Hong, Apostolia M. Tsimberidou, Aung Naing, Jennifer J. Wheler, Sarina A. Piha‐Paul, Filip Jankú, Manfred Klevesath, (unknown), Andreas Johne, Razelle Kurzrock	1
12	Phase I Dose-Escalation Study of Oral Selective C-Met Inhibitor Emd 1214063 in Patients with Advanced Solid Tumors 2012 ·Annals of Oncology ·Gerald S. Falchook, David S. Hong, Hesham M. Amin, Siqing Fu, Sarina A. Piha‐Paul, Manfred Klevesath, (unknown), Andreas Johne, Sofia Stinchi, Razelle Kurzrock	4
13	A Phase I Dose-Escalation Study of emd 1214063, an Oral Selective CMET Inhibitor, in Patients with Advanced Solid Tumors 2012 ·Annals of Oncology ·Aung Naing, Gerald S. Falchook, Siqing Fu, Hesham M. Amin, Sarina A. Piha‐Paul, David S. Hong, Apostolia M. Tsimberidou, Jennifer J. Wheler, Filip Jankú, Manfred Klevesath, (unknown), Andreas Johne, Razelle Kurzrock	2
14	1245 POSTER Phase I Dose-escalation Study of the Oral Selective C-Met Inhibitor EMD 1204831 in Patients With Advanced Solid Tumours 2011 ·European Journal of Cancer ·Gerald S. Falchook, Siqing Fu, (unknown), (unknown), David S. Hong, Aung Naing, Manfred Klevesath, M.R. Mattiacci, Andreas Johne, Razelle Kurzrock	3
15	Lymph Node Status and Breast Cancer-related Lymphedema 2007 ·Annals of Surgery ·Arnie Purushotham, (unknown), Manfred Klevesath, Patrick Chou, Olorunsola F. Agbaje, Stephen W. Duffy	45
16	The value of immunohistochemistry in sentinel lymph node histopathology in breast cancer 2005 ·British Journal of Cancer ·Manfred Klevesath, Lynda G. Bobrow, Sarah E. Pinder, Arnie Purushotham	31
17	Touch imprint cytology of core needle biopsy specimens: a useful method for immediate reporting of symptomatic breast lesions 2005 ·European Journal of Surgical Oncology ·Manfred Klevesath, (unknown), (unknown), (unknown), Eamonn Coveney	28
18	Morbidity After Sentinel Lymph Node Biopsy in Primary Breast Cancer: Results From a Randomized Controlled Trial 2005 ·Journal of Clinical Oncology ·Arnie Purushotham, Sara Upponi, Manfred Klevesath, Lynda G. Bobrow, Keith Millar, Jonathan P. Myles, Stephen W. Duffy	394
19	The Effect of Pramlintide (Amylin Analogue) Treatment on Bone Metabolism and Bone Density in Patients with Type 1 Diabetes Mellitus 1999 ·Hormone and Metabolic Research ·(unknown), Manfred Klevesath, Valentin Borcea, (unknown), Markus J. Seibel, Peter Wahl, R. Ziegler, Peter P. Nawroth	27

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact